Industry: Health-Biomedical Region: Europe and Central Asia Price: US $10 million Method: Equity investment
Details: The company is a multinational pharmaceutical and diagnostics company focused on in vitro diagnostics and cancer and transplant drugs manufacturer.
Details: The company is a multinational pharmaceutical and diagnostics company focused on in vitro diagnostics and cancer and transplant drugs manufacturer. The products mainly cover oncology, viral diseases, inflammation, metabolic diseases, central nervous diseases, clinical chemotherapy, immunology, urine analysis, blood screening, genetic diseases, infectious diseases and microbiology and other related drugs. Its main products include cancer drugs, which are also effective in the treatment of rheumatoid arthritis, anemia and osteoporosis. In addition, the company conducts research, development and production related to molecular diagnostic reagents, test systems and test kits, and provides automated instrumentation, software, consumables and information technology solutions for use in in vitro diagnostics and research. Some of the company's shareholders are selling their small stakes and exclusive licenses for new drugs in China in exchange for foreign currency investments of around 6 billion to 7 billion yuan.